MLV Capital rated Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) to Buy with price target $3.50
MLV Capital rated Sunesis Pharmaceuticals, Inc.
(NASDAQ: SNSS) to Buy with price target $3.50 with today's price of $1.27.
Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies.
is a boutique investment bank and institutional broker-dealer focused on providing independent financial advice and unique capital markets expertise to corporate and institutional clients in capital intensive industries such as metals and mining, life sciences, energy and real estate. With a focus on raising money efficiently for clients, MLV has rapidly become a leader in the At-the-Market(ATM) transaction market.